Eli Lilly’s and Regeneron’s EUA talk trigger prudence on available Covid-19 data

LY-CoV555 demonstrated an improvement in the Covid-related hospitalisation and emergency room visit secondary endpoint in all doses. Credit: Shutterstock.



  • EUA